Bristol-Myers to divest Celgene’s psoriasis drug to clear antitrust

As a condition of Federal Trade Commission approval for its takeover of Celgene, Bristol-Myers Squibb plans to sell off Otezla, a psoriasis drug made by Celgene that generated $1.6 billion of worldwide revenue in 2018.
Why it matters: The FTC seems worried B…
Read More


  • No comments yet.
  • Add a comment